| Dr Bright Chen, DPM | |
|
9889 Bellaire Blvd Ste E219a, Houston, TX 77036-3499 | |
| (713) 272-6688 | |
| (713) 271-6689 |
| Full Name | Dr Bright Chen |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 14 Years |
| Location | 9889 Bellaire Blvd Ste E219a, Houston, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063768729 | NPI | - | NPPES |
| 323451004 | Medicaid | TX | |
| 323451003 | Medicaid | TX | |
| 323451005 | Medicaid | TX | |
| 323451006 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | 2050 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Preferred Podiatry Group Pc | 3971412677 | 114 |
| Zhuodao Zhao | 9436119765 | 3 |
News Archive
Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat ocular diseases, announced today that Kala researchers will present preclinical data at the upcoming Controlled Release Society (CRS) 2013 Annual Meeting taking place July 21-24, 2013, in Honolulu, HI.
According to experts there is evidence that helmets help protect downhill skiers and snowboarders from head injuries, but more needs to be done to encourage helmet use.
NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the European Commission has granted orphan drug designation to Natpara (recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of hypoparathyroidism.
Hovione announced today it has filed its first Investigational New Drug (IND) Application with the U.S. Food and Drug Administration. This event represents a milestone in Hovione's strategy of developing improved drug delivery options for established drugs.
› Verified 9 days ago
| Provider Name | Zhuodao Zhao |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1437231008 PECOS PAC ID: 9436119765 Enrollment ID: O20041012000935 |
News Archive
Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat ocular diseases, announced today that Kala researchers will present preclinical data at the upcoming Controlled Release Society (CRS) 2013 Annual Meeting taking place July 21-24, 2013, in Honolulu, HI.
According to experts there is evidence that helmets help protect downhill skiers and snowboarders from head injuries, but more needs to be done to encourage helmet use.
NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the European Commission has granted orphan drug designation to Natpara (recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of hypoparathyroidism.
Hovione announced today it has filed its first Investigational New Drug (IND) Application with the U.S. Food and Drug Administration. This event represents a milestone in Hovione's strategy of developing improved drug delivery options for established drugs.
› Verified 9 days ago
| Provider Name | Preferred Podiatry Group Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1720037138 PECOS PAC ID: 3971412677 Enrollment ID: O20100601000697 |
News Archive
Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat ocular diseases, announced today that Kala researchers will present preclinical data at the upcoming Controlled Release Society (CRS) 2013 Annual Meeting taking place July 21-24, 2013, in Honolulu, HI.
According to experts there is evidence that helmets help protect downhill skiers and snowboarders from head injuries, but more needs to be done to encourage helmet use.
NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the European Commission has granted orphan drug designation to Natpara (recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of hypoparathyroidism.
Hovione announced today it has filed its first Investigational New Drug (IND) Application with the U.S. Food and Drug Administration. This event represents a milestone in Hovione's strategy of developing improved drug delivery options for established drugs.
› Verified 9 days ago
| Provider Name | Step Up Foot & Ankle Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1962886614 PECOS PAC ID: 4385952365 Enrollment ID: O20150925000410 |
News Archive
Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat ocular diseases, announced today that Kala researchers will present preclinical data at the upcoming Controlled Release Society (CRS) 2013 Annual Meeting taking place July 21-24, 2013, in Honolulu, HI.
According to experts there is evidence that helmets help protect downhill skiers and snowboarders from head injuries, but more needs to be done to encourage helmet use.
NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the European Commission has granted orphan drug designation to Natpara (recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of hypoparathyroidism.
Hovione announced today it has filed its first Investigational New Drug (IND) Application with the U.S. Food and Drug Administration. This event represents a milestone in Hovione's strategy of developing improved drug delivery options for established drugs.
› Verified 9 days ago
| Provider Name | Hmc Medical Associates, Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1437231008 PECOS PAC ID: 3274977293 Enrollment ID: O20240219000820 |
News Archive
Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat ocular diseases, announced today that Kala researchers will present preclinical data at the upcoming Controlled Release Society (CRS) 2013 Annual Meeting taking place July 21-24, 2013, in Honolulu, HI.
According to experts there is evidence that helmets help protect downhill skiers and snowboarders from head injuries, but more needs to be done to encourage helmet use.
NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the European Commission has granted orphan drug designation to Natpara (recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of hypoparathyroidism.
Hovione announced today it has filed its first Investigational New Drug (IND) Application with the U.S. Food and Drug Administration. This event represents a milestone in Hovione's strategy of developing improved drug delivery options for established drugs.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bright Chen, DPM 12335 Kingsride Ln # 437, Houston, TX 77024-4116 Ph: (281) 661-1986 | Dr Bright Chen, DPM 9889 Bellaire Blvd Ste E219a, Houston, TX 77036-3499 Ph: (713) 272-6688 |
News Archive
Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat ocular diseases, announced today that Kala researchers will present preclinical data at the upcoming Controlled Release Society (CRS) 2013 Annual Meeting taking place July 21-24, 2013, in Honolulu, HI.
According to experts there is evidence that helmets help protect downhill skiers and snowboarders from head injuries, but more needs to be done to encourage helmet use.
NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the European Commission has granted orphan drug designation to Natpara (recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of hypoparathyroidism.
Hovione announced today it has filed its first Investigational New Drug (IND) Application with the U.S. Food and Drug Administration. This event represents a milestone in Hovione's strategy of developing improved drug delivery options for established drugs.
› Verified 9 days ago
Lan D Ngo, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 12784 Veterans Memorial Dr, Foot Clinic, Houston, TX 77014 Phone: 281-895-7808 Fax: 281-895-6377 | |
Felix Spiegel, M.D. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 5373 W Alabama St, Suite 121, Houston, TX 77056 Phone: 713-960-0003 Fax: 713-960-0004 | |
Houston Foot And Ankle Care Podiatrist Medicare: Medicare Enrolled Practice Location: 2900 Weslayan St Ste 650, Houston, TX 77027 Phone: 713-541-3199 Fax: 713-541-5809 | |
Dr. Onya Victoria Lemar, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1213 Hermann Dr, Ste 250, Houston, TX 77004 Phone: 832-403-3221 Fax: 832-403-3223 | |
Andrea K Rockett, DPM Podiatrist Medicare: May Accept Medicare Assignments Practice Location: 1234 Bay Area Blvd, Suite G, Houston, TX 77058 Phone: 281-488-3237 Fax: 281-488-4218 | |
Dr. Cherese Andria Thomas-ramoutar, DPM Podiatrist Medicare: Medicare Enrolled Practice Location: 114 W Drew St, Houston, TX 77006 Phone: 713-533-0840 | |
Hadley Mcarthur, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 12121 Richmond Ave Ste 417, Houston, TX 77082 Phone: 281-597-1630 |